Loading clinical trials...
Loading clinical trials...
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Interventions
MEDI4736 in combination with nab-paclitaxel and gemcitabine
MEDI4736 in combination with AZD5069
Locations
7
United States
Research Site
Rochester, New York, United States
Research Site
Cambridge, United Kingdom
Research Site
Glasgow, United Kingdom
Research Site
London, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Start Date
March 25, 2016
Primary Completion Date
July 9, 2018
Completion Date
July 9, 2018
Last Updated
August 14, 2019
NCT06445062
NCT07165951
NCT07096362
NCT06168812
NCT05039177
NCT06904378
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions